Preclinical Studies of SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Preclinical Studies of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor (IL-3R), in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Potent Activity in BPDCN Cell Lines, Primary Tumor, and in an In Vivo Model. ASH 2013. Abstract | Poster
SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Possesses Preclinical Cytotoxic Activity Against Chronic Eosinophilic Leukemia
SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Possesses Preclinical Cytotoxic Activity against Chronic Eosinophilic Leukemia. ASH 2013. Abstract | Poster
SL-401, a Novel Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Inhibits Plasmacytoid Dendritic Cell (pDC)-Induced Myeloma Cell Growth and Overcomes Drug Resistance
SL-401, A Novel Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Inhibits Plasmacytoid Dendritic Cell (pDC)-induced Myeloma Cell Growth and Overcomes Drug Resistance. ASH 2013. Abstract | Poster
SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor on Cancer Stem Cells and Tumor Bulk, Has Broad Clinical Activity and Tolerability as a Single Agent in Patients With Advanced Hematological Malignancies
SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor on Cancer Stem Cells and Tumor Bulk, Has Broad Clinical Activity and Tolerability as a Single Agent in Patients with Advanced Hematological Malignancies. ASCO 2013. Abstract | Poster
Clinical and Preclinical Activity of SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor on Cancer Stem Cells and Tumor Bulk of Hematologic Malignancies, Against Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Clinical and Preclinical Activity of SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor on Cancer Stem Cells and Tumor Bulk of Hematologic Malignancies, Against Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). ASCO 2013. Abstract | Poster
A Novel Agent SL-401 Targeting Interleukin-3 (IL-3)-Receptor Blocks Plasmacytoid Dendritic Cell (pDC)-Induced Myeloma Cell Growth and Overcomes Drug Resistance
A Novel Agent SL-401 Targeting Interleukin-3 (IL-3)-Receptor Blocks Plasmacytoid Dendritic Cell (pDC)-induced Myeloma Cell Growth and Overcomes Drug Resistance. ASCO 2013. Abstract | Poster
SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML. ASH 2012.
SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML. ASH 2012. Abstract | Poster
The IL-3Rα-Targeted Drug SL-401 Selectively Kills Blastic Plasmacytoid Dendritic Cell Neoplasm Cells. ASH 2011.
The IL-3Rα-Targeted Drug SL-401 Selectively Kills Blastic Plasmacytoid Dendritic Cell Neoplasm Cells. ASH 2011. Abstract | Poster
Hodgkin's Lymphoma Cell Lines Have Up-Regulated IL-3 Receptor α (IL-3Rα) Expression and Are Sensitive to SL-401, an IL-3Rα-Targeted Drug
Hodgkin’s Lymphoma Cell Lines Have Up-regulated IL-3 Receptor α (IL-3Rα) Expression and are Sensitive to SL-401, an IL-3Rα-Targeted Drug. ASH 2011. Abstract | Poster